Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 424
- Registration Number
- NCT01059812
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
Effect of NN5401 in Japanese Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT01051102
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 530
- Registration Number
- NCT01045707
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT01045447
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kahramanmaras, Turkey
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT01046110
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
Phase 1
Terminated
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: '2-0453Drug: NNC 0070-0002-0453Drug: placebo
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 117
- Registration Number
- NCT01044108
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Evansville, Indiana, United States
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT01043510
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- Drug: placebo
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT01038674
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland
A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Healthy
- Interventions
- Drug: NN9924 (oral)Drug: placeboDrug: NN9924 (s.c.)Drug: NN9924 (i.v.)
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 155
- Registration Number
- NCT01037582
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®
Phase 1
Completed
- Conditions
- HealthyGrowth Hormone Disorder
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 56
- Registration Number
- NCT01034202
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Hvidovre, Denmark
© Copyright 2025. All Rights Reserved by MedPath